Key Highlights

  • The screener's 91 health technology names show the weakest median one-week return of any sector at negative 3.49%, with a median one-month return of negative 3.82%, as of October 8, 2026.
  • The cap-weighted measure is milder, negative 2.48% for the week and negative 0.80% for the month, so large names held up better than the median, with 2 names at highs and 4 at lows.
  • Health Care Select Sector SPDR Fund (NYSEARCA:XLV) traded near USD 165.66, down 1.87%, at about 11 a.m. ET on October 8, 2026, in published market data, as Eli Lilly fell about 4.03%.
  • Eli Lilly (NYSE:LLY), Johnson & Johnson, AbbVie, Merck and UnitedHealth hold 15.49%, 10.15%, 7.81%, 5.74% and 5.50% of the fund, so one drug maker can swing its day.

What the Screener Shows

The screener splits healthcare into health technology, which typically covers drug makers, biotechs and devices, and health services, which typically covers insurers and care providers. Health technology is last of 20 sectors on median one-week return, and Consumer Durables is next at negative 1.31%, far milder. Health services is different, with a median one-week gain of 0.99% and a cap-weighted gain of 1.31%, though its one-month cap-weighted return is negative 1.78%. The two groups do not map exactly to the fund's GICS sector, and these are screener-computed figures. Healthcare was among the groups that gained on October 7, so October 8 reverses part of that move, though no sector return was verified.

The Lilly Effect

Eli Lilly (NYSE:LLY) traded near USD 1,140.80 at about 11 a.m. ET, down 4.03% and about 11.8% below its 52-week high of USD 1,292.65, simple arithmetic. At a 15.49% weight, that drop explains roughly 0.62 points of the fund's 1.87% fall, about one third, though weights and prices come from different times. No verified cause was found for the decline, which may reflect profit taking or news not captured here. On October 7 the World Health Organization issued childhood obesity guidelines that discourage weight-loss drugs for children under 10, and Cantor Fitzgerald raised its Lilly target to USD 1,440 on October 8, so analysts have not turned negative.

Risks and Dates to Watch

Single-name trial risk can hit the group quickly, and one failed study can erase months of gains. On October 8 argenx (NASDAQ:ARGX) fell about 15.9% premarket to USD 781.00 after an independent committee recommended stopping its Phase 3 UNITY study for futility. Rising yields also pressure long-duration biotechs, because their profits lie far in the future and are discounted more heavily when rates climb. Dates include argenx third quarter results on October 22, Eli Lilly (NYSE:LLY) results on October 29 and September CPI on October 14 at 8:30 a.m. ET, a Key Rate input. The fund yields 1.54%, charges 0.08% and holds about USD 42.81 billion.

Where Things Stand

Health technology is the worst sector this week because the typical drug, biotech and device stock fell 3.49% while a few large names held better, including Health Care Select Sector SPDR Fund (NYSEARCA:XLV) heavyweights. A 4.03% drop in Eli Lilly accounts for roughly a third of the fund's 1.87% intraday decline on October 8, and trial setbacks such as argenx added pressure. Breadth is poor, with 2 names at highs and 4 at lows. October 14 CPI and late-October Earnings are the next tests.